American Journal of Respiratory Medicine

, Volume 1, Issue 4, pp 235–241

Macrolides in Cystic Fibrosis

Is There a Role?
  • Joanne M. Wolter
  • Sharon L. Seeney
  • Joseph G. McCormack
Current Opinion


A spectrum of anti-inflammatory properties, evidence of anti-infective action against Pseudomonas aeruginosa at sub-inhibitory concentrations and positive clinical experience in patients with diffuse panbronchiolitis, a disease with features in common with cystic fibrosis (CF), has prompted research to evaluate the role of macrolide therapy in patients with CF. Newer macrolides such as azithromycin have the advantage of improved tolerability and a prolonged intracellular half-life requiring an infrequent dosing regimen.

Results from initial studies suggest a benefit from several months of macrolide therapy in patients with CF. An improvement in lung function was initially shown in a small open study in children, while maintenance of lung function compared with placebo, reduced acute respiratory exacerbations, and reduced systemic markers of inflammation were demonstrated in a randomized, placebo-controlled study of macrolide therapy in adult patients with CF.

Additional controlled studies are required to determine optimal drug, dosage, and duration of therapy, and long-term adverse effects of prolonged therapy with macrolides in patients with CF. The potential, with long-term use, to induce resistance against other bacteria colonizing the upper respiratory tract e.g. pneumococci has not been explored.

Measurement of cytokines and inflammatory mediators from the sputum of patients with CF is technically difficult and does not correlate with disease activity. There is a need for easily measurable, reproducible and clinically meaningful end-points for evaluation of new therapies in CF. The choice of appropriate outcome measures, apart from lung function, to monitor disease activity needs careful consideration in clinical trials determining the efficacy of macrolides in patients with CF.

Evidence-based recommendations for the use of macrolides in the treatment of CF are not expected for some years although macrolides are already being prescribed for long-term use in some centers. There is a need for further research into mechanisms of anti-inflammatory action of macrolides in the lungs of patients with CF and whether or not such therapy may be beneficial in the long term.


  1. 1.
    Doull IJ. Recent advances in cystic fibrosis. Arch Dis Child 2001; 85: 62–6PubMedCrossRefGoogle Scholar
  2. 2.
    Thompson AB, Smits WL, Fick RB. Immunomodulatory therapies for cystic fibrosis. Semin Respir Infect 1992; 7(3): 218–26PubMedGoogle Scholar
  3. 3.
    Lai H-C, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone therapy in children with cystic fibrosis. N Engl J Med 2000; 342: 851–9PubMedCrossRefGoogle Scholar
  4. 4.
    Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848–54PubMedCrossRefGoogle Scholar
  5. 5.
    Koch C, McKenzie SG, Kaplowitz H, et al. International practice patterns by age and severity of lung disease in cystic fibrosis: data from the epidemiologic registry of cystic fibrosis (ERCF). Pediatr Pulmonol 1997; 24: 147–54PubMedCrossRefGoogle Scholar
  6. 6.
    Konstan MW. Therapies aimed at airway inflammation in cystic fibrosis. Clin Chest Med 1998; 19: 505–13PubMedCrossRefGoogle Scholar
  7. 7.
    Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis. Chest 1999; 115: 1053–8PubMedCrossRefGoogle Scholar
  8. 8.
    Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med 1998; 4: 116–21PubMedCrossRefGoogle Scholar
  9. 9.
    Tanimoto H. A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan. Antibiot Chemother 1991; 44: 94–8PubMedGoogle Scholar
  10. 10.
    Keicho N, Kudoh S. Diffuse panbronchiolitis: role of macrolides in therapy. Am J Respir Med 2002; 1(2): 119–31PubMedCrossRefGoogle Scholar
  11. 11.
    Ichikawa Y, Ninomiya H, Koga H, et al. Erythomycin reduces neutrophils and neutriphil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis. Am Rev Respir Dis 1992; 146: 196–203PubMedGoogle Scholar
  12. 12.
    Kobayashi H, Takeda H, Sakayori S, et al. Study on azithromycin in treatment of diffuse panbronchiolitis [abstract 6]. Kansenshogaku Zasshi 1995; 69: 711–22PubMedGoogle Scholar
  13. 13.
    Carbon C. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 1995; 23: S10–4PubMedCrossRefGoogle Scholar
  14. 14.
    Kawamura-Sato K, Iinuma Y, Hasegawa T, et al. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 2000; 44: 2869–72PubMedCrossRefGoogle Scholar
  15. 15.
    Mizukane R, Hirakata Y, Kaku M, et al. Comparative in vitro exoenzyme suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38(3): 528–33PubMedCrossRefGoogle Scholar
  16. 16.
    Molinari G, Guzman CA, Pesce A, et al. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31: 681–8PubMedCrossRefGoogle Scholar
  17. 17.
    Howe RA, Spencer RC. Macrolides for the treatment of Pseudomonas aeruginosa infections. J Antimicrob Chemother 1997; 40: 153–5PubMedCrossRefGoogle Scholar
  18. 18.
    Tateda K, Ishi Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependant bacteriocidal activity and inhibition of protein synthesis by erythromycin, clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40(10): 2271–5PubMedGoogle Scholar
  19. 19.
    Sakata K, Yajima H, Tanaka K, et al. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Resp Dis 1993; 148: 1061–5PubMedCrossRefGoogle Scholar
  20. 20.
    Ichimiya T, Takeoka K, Hiramatsu K, et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996; 42: 186–91PubMedCrossRefGoogle Scholar
  21. 21.
    Baumann U, Fischer JJ, Gudowius P, et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection 2000; 29: 7–11CrossRefGoogle Scholar
  22. 22.
    Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001 Jun; 31(6): 464–73PubMedCrossRefGoogle Scholar
  23. 23.
    Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429(1–3): 209–29PubMedCrossRefGoogle Scholar
  24. 24.
    Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998; 41Suppl. B: 37–46PubMedCrossRefGoogle Scholar
  25. 25.
    Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001;13: 3–8PubMedGoogle Scholar
  26. 26.
    Villagrasa V, Berto L, Cortijo J, et al. Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes. Gen Pharmacol 1997; 29(4): 605–9PubMedCrossRefGoogle Scholar
  27. 27.
    Sugihara E. Effect of macrolide antibiotics on neutrophil function in human peripheral blood [abstract 4]. Kansenshogaku Zasshi 1997; 71: 359–36Google Scholar
  28. 28.
    Okubo Y. Macrolides reduce the expression of surface mac-1 molecule on neutrophils. Kurume Med J 1997; 44: 115–23PubMedCrossRefGoogle Scholar
  29. 29.
    Richman-Eisenstat JY, Jorens PG, Hebert CA, et al. Interleukin-8: an important chemoattractant in sputum of patients with chronic airways disease. Am J Physiol 1993; 264: L413–8PubMedGoogle Scholar
  30. 30.
    Wolter JM, Rodwell RL, Bowler SD, et al. Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis. Clin Diag Lab Immunol 1999; 6(2): 260–5Google Scholar
  31. 31.
    Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111–8PubMedGoogle Scholar
  32. 32.
    Sakito O, Kadota J, Kohno S, et al. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63(1): 42–8PubMedCrossRefGoogle Scholar
  33. 33.
    Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 1995; 210(3): 781–6PubMedCrossRefGoogle Scholar
  34. 34.
    Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156: 266–71PubMedGoogle Scholar
  35. 35.
    Desaki M, Takizawa H, Ohtosh T, et al. Erythromycin suppresses nuclear factor-kappa B and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000; 267(1): 124–8PubMedCrossRefGoogle Scholar
  36. 36.
    Abe S, Nakomura H, Inove S, et al. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000; 22(1): 51–60PubMedGoogle Scholar
  37. 37.
    Elborn JS, Cordon SM, Parker D, et al. The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Respir Med 1993; 87: 603–7PubMedCrossRefGoogle Scholar
  38. 38.
    Greally P, Hussein MJ, Cook AJ, et al. Sputum tumor necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993; 68: 389–92PubMedCrossRefGoogle Scholar
  39. 39.
    Kronborg G, Hansen MB, Svenson M, et al. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol 1993; 15: 292–7PubMedCrossRefGoogle Scholar
  40. 40.
    Iino Y, Toriyama M, Natori Y, et al. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol 1992; 101: 16–20Google Scholar
  41. 41.
    Bell SC, Wolter JM, Seeney SL, et al. Azithromycin (AZM) reduces TNF-α release from lipopolysaccharide (LPS)-stimulated mononuclear cells (PBMC) in cystic fibrosis (CF) [abstract]. Pediatr Pulmonol 2000; 20: 260Google Scholar
  42. 42.
    Neu HC. Clinical microbiology of azithromycin. Am J Med 1991; 91: S12–8CrossRefGoogle Scholar
  43. 43.
    Nakamura H, Yoshimura K, McElvaney NG, et al. Neutrophil elastase in respiratory epithelial lining fluid in individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992; 89: 1478–84PubMedCrossRefGoogle Scholar
  44. 44.
    Meyer KC, Lewandowski JR, Zimmerman JJ, et al. Human neutrophil elastase and elastase/alpha-1-antiprotease complex in cystic fibrosis. Am Rev Respir Dis 1991; 144: 580–5PubMedCrossRefGoogle Scholar
  45. 45.
    Hollsing AE, Lantz B, Bergstrom K, et al. Granulocyte elastase-alpha-1-antiproteinase complex in cystic fibrosis: sensitive plasma assay for monitoring pulmonary infections. J Pediatr 1987; 111: 206–11PubMedCrossRefGoogle Scholar
  46. 46.
    Ordonez CL, Stulbarg M, Grudland H, et al. Effect of clarithromcin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001; 32: 29–37PubMedCrossRefGoogle Scholar
  47. 47.
    Altschuler EL. Azithromycin, the multidrug-resistant protein and cystic fibrosis [letter]. Lancet 1998; 351: 1286PubMedCrossRefGoogle Scholar
  48. 48.
    Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis [letter]. Lancet 1998; 351: 420PubMedCrossRefGoogle Scholar
  49. 49.
    Wolter JM, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57(3): 212–6PubMedCrossRefGoogle Scholar
  50. 50.
    Dean TP, Dai Y, Shute JK, et al. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, and sera of children with cystic fibrosis. Pediatr Res 1993; 34: 159–61PubMedCrossRefGoogle Scholar
  51. 51.
    Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997 Feb; 41(2): 161–5PubMedCrossRefGoogle Scholar
  52. 52.
    Pirzada OM, Taylor CJ. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis [abstract]. Pediatr Pulmonol 1999; 28Suppl. 19: 263Google Scholar
  53. 53.
    Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis (Cochrane Review). In: The Cochrane Database of Systematic Reviews. Available from The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2001Google Scholar
  54. 54.
    Anstead MI, Kuhn RJ, Halsey S, et al. Prolonged beneficial effect of chronic azithromycin therapy on lung function in cystic fibrosis. Pediatr Pulmonol 2000; Suppl. 20: 244Google Scholar
  55. 55.
    Equi A, Bush A, Alton EW, et al. A prospective, double-bind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatr Pulmonol 2001; Suppl. 22: 307Google Scholar
  56. 56.
    Oldfield EC, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomised, double-blind, placebo-controlled multicenter trial. Clin Infect Dis 1998; 26: 611–9PubMedCrossRefGoogle Scholar
  57. 57.
    Maeda K, Mikasa K, Konishi M, et al. Acute exacerbations due to Streptococcus pneumoniae in chronic respiratory infections during long-term macrolide therapy. Kansenshogaku Zasshi 2001 Oct; 75(10): 846–50PubMedGoogle Scholar
  58. 58.
    Govan JR, Hughes JE, Vandamme P. Burkholderia cepacia: medical; taxonomic and ecological issues. J Med Microbiol 1996; 45: 395–407PubMedCrossRefGoogle Scholar
  59. 59.
    Abbott J, Dodd M, Bilton D, et al. Treatment compliance in adults with cystic fibrosis. Thorax 1994; 49: 115–20PubMedCrossRefGoogle Scholar
  60. 60.
    Conway SP, Pond MN, Hamnett T, et al. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996; 51: 29–33PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Joanne M. Wolter
    • 1
  • Sharon L. Seeney
    • 1
  • Joseph G. McCormack
    • 1
  1. 1.University Department of MedicineMater Adult HospitalBrisbaneAustralia
  2. 2.GlaxoSmithKline BiologicalsRixensartBelgium

Personalised recommendations